Last reviewed · How we verify
MP0250
At a glance
| Generic name | MP0250 |
|---|---|
| Sponsor | Molecular Partners AG |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- MP0250 DARPin® Protein Plus Osimertinib in Patients With EGFR-mutated NSCLC (PHASE1)
- A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple Myeloma (PHASE1, PHASE2)
- First-in-human Study to Investigate the Safety, Tolerability and Blood Levels of the Test Drug MP0250 in Cancer Patients (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MP0250 CI brief — competitive landscape report
- MP0250 updates RSS · CI watch RSS
- Molecular Partners AG portfolio CI